207 related articles for article (PubMed ID: 32851809)
21. Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults deficient in CYP2D6 activity: a double-blind, randomized clinical trial.
Cahn A; Mehta R; Preece A; Blowers J; Donald A
Clin Drug Investig; 2013 Sep; 33(9):653-64. PubMed ID: 23881566
[TBL] [Abstract][Full Text] [Related]
22. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.
Lukina E; Watman N; Arreguin EA; Banikazemi M; Dragosky M; Iastrebner M; Rosenbaum H; Phillips M; Pastores GM; Rosenthal DI; Kaper M; Singh T; Puga AC; Bonate PL; Peterschmitt MJ
Blood; 2010 Aug; 116(6):893-9. PubMed ID: 20439622
[TBL] [Abstract][Full Text] [Related]
23. Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studies.
Cahn A; Tal-Singer R; Pouliquen IJ; Mehta R; Preece A; Hardes K; Crater G; Deans A
Clin Drug Investig; 2013 Jul; 33(7):477-88. PubMed ID: 23784369
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
25. A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers.
Xiao F; Zhang F; Zhang LL; Wei W
Eur J Clin Pharmacol; 2018 Jan; 74(1):69-77. PubMed ID: 29051989
[TBL] [Abstract][Full Text] [Related]
26. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
[TBL] [Abstract][Full Text] [Related]
27. Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age.
Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
Clin Ther; 2016 Jan; 38(1):39-52. PubMed ID: 26581327
[TBL] [Abstract][Full Text] [Related]
28. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
29. Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3.
Wilson MW; Shu L; Hinkovska-Galcheva V; Jin Y; Rajeswaran W; Abe A; Zhao T; Luo R; Wang L; Wen B; Liou B; Fannin V; Sun D; Sun Y; Shayman JA; Larsen SD
ACS Chem Neurosci; 2020 Oct; 11(20):3464-3473. PubMed ID: 33035424
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of Cenobamate: Results From Single and Multiple Oral Ascending-Dose Studies in Healthy Subjects.
Vernillet L; Greene SA; Kamin M
Clin Pharmacol Drug Dev; 2020 May; 9(4):428-443. PubMed ID: 32087001
[TBL] [Abstract][Full Text] [Related]
31. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models.
Sardi SP; Viel C; Clarke J; Treleaven CM; Richards AM; Park H; Olszewski MA; Dodge JC; Marshall J; Makino E; Wang B; Sidman RL; Cheng SH; Shihabuddin LS
Proc Natl Acad Sci U S A; 2017 Mar; 114(10):2699-2704. PubMed ID: 28223512
[TBL] [Abstract][Full Text] [Related]
32. A phase I dose-ranging study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of AVN944, an IMPDH inhibitor, in healthy male volunteers.
Hamilton JM; Harding MW; Genna T; Bol DK
J Clin Pharmacol; 2009 Jan; 49(1):30-8. PubMed ID: 18971325
[TBL] [Abstract][Full Text] [Related]
33. Safety, Tolerability and Pharmacokinetics of Yimitasvir Phosphate Capsule, a Novel Oral Hepatitis C Virus NS5A Inhibitor, in Healthy Chinese Volunteers.
Zhao N; Xie R; Zhao X; Zhao H; Jia B; Zhang Y; Luo L; Huang Z; Li J; Wang X; Yan H; He B; Xie H; Ren Q; Cui Y
Clin Drug Investig; 2019 Jul; 39(7):671-681. PubMed ID: 31079356
[TBL] [Abstract][Full Text] [Related]
34. First-in-Human Pharmacokinetics and Safety Study of GSK3008356, a Selective DGAT1 Inhibitor, in Healthy Volunteers.
Okour M; Gress A; Zhu X; Rieman D; Lickliter JD; Brigandi RA
Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1088-1099. PubMed ID: 30950565
[TBL] [Abstract][Full Text] [Related]
35. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.
Chien SC; Wong FA; Fowler CL; Callery-D'Amico SV; Williams RR; Nayak R; Chow AT
Antimicrob Agents Chemother; 1998 Apr; 42(4):885-8. PubMed ID: 9559801
[TBL] [Abstract][Full Text] [Related]
36. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.
Stoch SA; Zajic S; Stone JA; Miller DL; van Bortel L; Lasseter KC; Pramanik B; Cilissen C; Liu Q; Liu L; Scott BB; Panebianco D; Ding Y; Gottesdiener K; Wagner JA
Br J Clin Pharmacol; 2013 May; 75(5):1240-54. PubMed ID: 23013236
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
[TBL] [Abstract][Full Text] [Related]
38. Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement.
Guérard N; Oder D; Nordbeck P; Zwingelstein C; Morand O; Welford RWD; Dingemanse J; Wanner C
Clin Pharmacol Ther; 2018 Apr; 103(4):703-711. PubMed ID: 28699267
[TBL] [Abstract][Full Text] [Related]
39. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver-Targeting Acetyl-CoA Carboxylase Inhibitor (PF-05221304): A Three-Part Randomized Phase 1 Study.
Bergman A; Carvajal-Gonzalez S; Tarabar S; Saxena AR; Esler WP; Amin NB
Clin Pharmacol Drug Dev; 2020 May; 9(4):514-526. PubMed ID: 32065514
[TBL] [Abstract][Full Text] [Related]
40. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects.
Kato M; Furuie H; Shimizu T; Miyazaki A; Kobayashi F; Ishizuka H
Br J Clin Pharmacol; 2018 Aug; 84(8):1821-1829. PubMed ID: 29688582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
